Please assess the completion status of the following clinical trial:

Trial Title: Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Each subject must meet all of the following inclusion criteria during the screening process in order to participate in the study:~* Subjects must have a diagnosis of sickle cell disease (SS, SC, S-beta-thalassemia), other hemoglobinopathies, or hemolytic disorders, such as hereditary spherocytosis.~* Be at least 18 years old.~* Have a leg ulcer of at least 4 weeks (28 days) duration.~* Leg ulcer must be no smaller than 2.5 cm(2) and no larger than 100 cm(2).~* Provide written informed consent.~EXCLUSION CRITERIA:~Subjects meeting any of the following criteria during baseline evaluation will be excluded from entry into the study:~* Exposure to therapeutic nitric oxide, L-arginine, nitroprusside or nitroglycerine within the past 1 week.~* Subjects presenting with clinically diagnosed bacterial infection (e.g., osteomyelitis, pneumonia, sepsis or meningitis).~* Subjects who have a pre-existing methemoglobinemia (more than 2.5 percent), unless the cytochrome b5 reductase (methemoglobin reductase) is within normal limits and the methemoglobin is no greater than 3 percent)~* Patients who are currently enrolled in any other investigational drug study (this does not include observational or natural history protocols).~* Use of PDE5 inhibitors, such as sildenafil, 4 days prior to screening.~* Pregnant women (urine or serum HCG plus) or nursing mothers.~* The following list of drugs and agents may cause methemoglobinemia and should be avoided while on this study:~  * Anesthetics (local): Benzocaine, procaine, prilocaine, Anbesol, Orajel~ * Antimalarials: chloroquine, primaquine, quinacrine~ * Aniline dyes~ * Chlorates~ * Dapsone~ * Diarylsulfonylureas~ * Doxorubicin~ * Metoclopramide~ * Nitric and nitrous oxide~ * Nitrobenzenes (shoe and floor polish and in paint solvents)~ * Nitroethane (artificial nail remover, propellent, fuel additive)~ * Nitrofurantoin (furadantin)~ * Pyridium (phenazopyridine)~ * Phenacetin (acetaminophen)~ * Phenylhydrazine~ * Rasburicase~ * Sulfonamides (sulfacetamide, sulfamethoxazole, sulfanilamide, sulfapyridine)~    * If a subject participant meets exclusion criteria while participating in the trial, then the subject will be removed from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).